Kaiser, J. Personalized tumour vaccines keep cancer in check. Science 356, 122 (2017).
Pulendran, B. & Davis, M. M. The science and medicine of human immunology. Science 369, eaay4014 (2020).
Ci, T. et al. Cryo-shocked cancer cells for targeted drug delivery and vaccination. Sci. Adv. 6, eabc3013 (2020).
Jiang, Y. et al. Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity. Adv. Mater. 32, e2001808 (2020).
Guo, J. et al. Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns. Nat. Biomed. Eng. 6, 19–31 (2022).
Harari, A., Graciotti, M., Bassani-Sternberg, M. & Kandalaft, L. E. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat. Rev. Drug Discov. 19, 635–652 (2020).
Marar, C., Starich, B. & Wirtz, D. Extracellular vesicles in immunomodulation and tumor progression. Nat. Immunol. 22, 560–570 (2021).
Cheng, L. & Hill, A. F. Therapeutically harnessing extracellular vesicles. Nat. Rev. Drug Discov. 21, 379–399 (2022).
Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298–312 (2021).
Roth, G. A. et al. Designing spatial and temporal control of vaccine responses. Nat. Rev. Mater. 7, 174–195 (2022).
Ma, L. et al. Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells. Adv. Mater. 33, e2104849 (2021).
Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).
Zhang, X., Cui, H., Zhang, W., Li, Z. & Gao, J. Engineered tumor cell-derived vaccines against cancer: the art of combating poison with poison. Bioact. Mater. 22, 491–517 (2023).
Page, D. B. et al. Glimpse into the future: harnessing autophagy to promote antitumour immunity with the DRibbles vaccine. J. Immunother. Cancer 4, 25 (2016).
Wenger, T. et al. Autophagy inhibition promotes defective neosynthesized proteins storage in ALIS, and induces redirection toward proteasome processing and MHCI-restricted presentation. Autophagy 8, 350–363 (2012).
Yi, Y. et al. Autophagy-assisted antigen cross-presentation: autophagosome as the argo of shared tumour-specific antigens and DAMPs. Oncoimmunology 1, 976–978 (2012).
Hou, W. et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 4, e966 (2013).
Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100–105 (2020).
MacNabb, B. W. et al. Dendritic cells can prime antitumour CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity 55, 982–997.e8 (2022).
Dersh, D., Holly, J. & Yewdell, J. W. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat. Rev. Immunol. 21, 116–128 (2021).
Li, Y. et al. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin. Cancer Res. 17, 7047–7057 (2011).
Li, Y. et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 68, 6889–6895 (2008).
Ye, Z. et al. Manipulation of PD-L1 endosomal trafficking promotes anticancer immunity. Adv. Sci. 10, e2206411 (2022).
Raudenska, M., Balvan, J. & Masarik, M. Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers. Mol. Cancer 20, 140 (2021).
Wen, Z. F. et al. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. J. Immunother. Cancer 6, 151 (2018).
Sanborn, R. E. et al. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. J. Immunother. Cancer 5, 103 (2017).
Diao, L. & Liu, M. Rethinking antigen source: cancer vaccines based on whole tumor cell/tissue lysate or whole tumor cell. Adv. Sci. 10, e2300121 (2023).
Wang, H. et al. GABARAPs regulate PI4P-dependent autophagosome:lysosome fusion. Proc. Natl Acad. Sci. USA 112, 7015–7020 (2015).
Sun, H. Q. et al. PI4P-dependent targeting of ATG14 to mature autophagosomes. Biochemistry 61, 722–729 (2022).
Cebollero, E. et al. Phosphatidylinositol-3-phosphate clearance plays a key role in autophagosome completion. Curr. Biol. 22, 1545–1553 (2012).
van Niel, G., D’Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018).
Martens, S., Nakamura, S. & Yoshimori, T. Phospholipids in autophagosome formation and fusion. J. Mol. Biol. 428, 4819–4827 (2016).
Zhao, Y. G., Codogno, P. & Zhang, H. Machinery, regulation and pathophysiological implications of autophagosome maturation. Nat. Rev. Mol. Cell Biol. 22, 733–750 (2021).
Shinoda, S. et al. Syntaxin 17 recruitment to mature autophagosomes is temporally regulated by PI4P accumulation. eLife 12, RP92189 (2024).
Laczkó-Dobos, H. et al. PtdIns4P is required for the autophagosomal recruitment of STX17 (syntaxin 17) to promote lysosomal fusion. Autophagy 20, 1639–1650 (2024).
Chen, D. et al. A mammalian autophagosome maturation mechanism mediated by TECPR1 and the Atg12-Atg5 conjugate. Mol. Cell 45, 629–641 (2012).
Nakamura, S. & Yoshimori, T. New insights into autophagosome–lysosome fusion. J. Cell Sci. 130, 1209–1216 (2017).
Johnson, D., Qiao, Z., Uwadiunor, E. & Djire, A. Holdups in nitride MXene’s development and limitations in advancing the field of MXene. Small 18, e2106129 (2022).
Marino, G., Niso-Santano, M., Baehrecke, E. H. & Kroemer, G. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 15, 81–94 (2014).
Debnath, J., Gammoh, N. & Ryan, K. M. Autophagy and autophagy-related pathways in cancer. Nat. Rev. Mol. Cell Biol. 24, 560–575 (2023).
Clarke, A. J. & Simon, A. K. Autophagy in the renewal, differentiation and homeostasis of immune cells. Nat. Rev. Immunol. 19, 170–183 (2019).
Zhao, J. et al. In situ growth of nanoantioxidants on cellular vesicles for efficient reactive oxygen species elimination in acute inflammatory diseases. Nano Today 40, 101282 (2021).
Murshid, A., Gong, J., Stevenson, M. A. & Calderwood, S. K. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev. Vaccines 10, 1553–1568 (2011).
Lhuillier, C. et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J. Clin. Invest. 131, e138740 (2021).
Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).
Qin, H. et al. Development of a cancer vaccine using in vivo click-chemistry-mediated active lymph node accumulation for improved immunotherapy. Adv. Mater. 33, e2006007 (2021).
Song, T. et al. Engineering the deformability of albumin-stabilized emulsions for lymph-node vaccine delivery. Adv. Mater. 33, e2100106 (2021).
Gong, T., Liu, L., Jiang, W. & Zhou, R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat. Rev. Immunol. 20, 95–112 (2020).
Marichal, T. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 17, 996–1002 (2011).
Gou, S. et al. Engineered nanovaccine targeting Clec9a+ dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist. Nano Lett. 21, 9939–9950 (2021).
Xu, J. et al. A general strategy towards personalized nanovaccines based on fluoropolymers for postsurgical cancer immunotherapy. Nat. Nanotechnol. 15, 1043–1052 (2020).
Zhao, J. et al. A minimalist binary vaccine carrier for personalized postoperative cancer vaccine therapy. Adv. Mater. 34, e2109254 (2022).
Lin, Z. J., Zhuo, M. J., Li, M. S., Wang, J. Y. & Zhou, Y. C. Synthesis and microstructure of layered-ternary Ti2AlN ceramic. Scr. Mater. 56, 1115–1118 (2007).
